azithromycin - versus control - for COVID-19 pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.00 [0.90, 1.12]< 10%1 study (1/-)50.0 %some concernnot evaluable moderatecrucial-
deaths (time to event analysis only) 1.00 [0.90, 1.12]< 10%1 study (1/-)50.0 %some concernnot evaluable moderatecrucial-
death or ventilation 0.97 [0.88, 1.06]< 10%1 study (1/-)74.2 %some concernnot evaluable moderateimportant-
hospital discharge 1.03 [0.97, 1.10]> 10%1 study (1/-)82.2 %some concernnot evaluable moderateimportant-

safety endpoints 00

arrhythmia 1.00 [0.76, 1.31]< 10%1 study (1/-)50.9 %some concernnot evaluable moderatenon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.